BioVentrix

• 14/04/2023
• Series A
• $48,500,000

BioVentrix is a privately held medical device company headquartered in San Ramon, CA, USA. Our mission is to improve and expand the treatment available for congestive heart failure (CHF) caused by ischemic cardiomyopathy, through the development of less invasive, catheter-based approaches.

BioVentrix offers benefits to all stakeholders in heart failure:

Patient – improved survival and QOL by treating the underlying cause of HF less invasively
Payor – reduced hospitalizations and avoidance of more expensive, highly invasive procedures like transplant and LVAD
Provider – become a pioneer in heart failure and offer unique solutions to your patients, in the growing and most expensive disease state in the world

---

---